Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical Oncology: Case Reports
Dirk Hellwig Author
Subjects of specialization
Affiliation
cancer, cancer oncology, Carcinogenesis
Department of Nuclear Medicine, University Hospital Regensburg, Franz-Josef- Strauss-Allee 11, D-93053 Regensburg, Germany
Biography
Dr. Dirk Hellwig is working as scientist and professor at Department of Nuclear Medicine, University Hospital Regensburg, Franz-Josef- Strauss-Allee 11, D-93053 Regensburg, Germany . The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy
Publications
Case Report Open Access
Disease Progression after Discontinuation of Nivolumab for Intolerable ImmunotherapyAssociated Polymyalgia Rheumatica in a Patient with Metastasized Adrenocortical Carcinoma: A Case Report and Review of the Literature
Author(s): Dennis Christoph Harrer*, Laura Landwehr, Matthias Kroiss, Dirk Hellwig, Christina Wendl Wolfgang Herr, Tobias Pukrop and Martin Vogelhuber (Germany)
Background: Metastasized Adrenocortical Carcinoma (ACC) ranks high among tumors with a dismal prognosis. Antibodies blocking PD-1, such as nivolumab, have proven efficacy against a variety of metastasized malignancies. In this case report, we present a long-term survivor with metastasized ACC who responded well to treatment with nivolumab but showed disease progression after discontinuation of PD-1 blockade due to intolerable immunotherapyassociated Polymyalgia Rheumatica (PMR). Case Presentation: A 38-year-old woman was subjected to adrenalectomy due to newly diagnosed adrenocortical carcinoma. Over the next 15 years, multiple metastases were treated using surgery, radiotherapy, chemotherapy, mitotane and targeted radionuclide therapy. The histological examination of brain metastases t... view more»
Google Scholars / Researchers Sites
